Integrated Filing — IndAS



General information about company
Scrip Code 543427
NSE Symbol MEDPLUS
MSEI Symbol NOTLISTED
ISIN INE804L01022
Name of company Medplus Health Services Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 27-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 25-Mar-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment In accordance with Ind AS 108, Operating Segments, segment information has been given in the consolidated financial statements of MedPlus Health Services Private Limited and therefore no separate disclosure on segment information is given in these standalone financial statements
Start date and time of board meeting 27-May-2025   15:30:00
End date and time of board meeting 27-May-2025   16:50:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2021-08-03
Indicate Company website link for updated RPT policy of the Company https://www.medplusindia.com/uploads/content/Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Declaration of unmodified opinion or statement on impact of audit qualificationtDeclaration of unmodified opinion nWhether the company has any related party?tYes nWhether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?tYes n(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/publictNA n(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank’s staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.tNA n(III) Whether the company is a ‘high value debt listed entity’ according to regulation 15 (1A)?tNo n(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?t n(b) If answer to above question is No, please explain the reason for not complying.t nWhether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?tYes nLatest Date on which RPT policy is updatedt03-08-2021 nIndicate Company website link for updated RPT policy of the Companythttps://www.medplusindia.com/uploads/content/Related-Party-Transaction-Policy.pdf nWhether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?tNo nNo. of times funds raised during the quartert nWhether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?tNo



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 2017510000 7130970000
Other income 26510000 89350000
Total income 2044020000 7220320000
2 Expenses
(a) Cost of materials consumed 195480000 616180000
(b) Purchases of stock-in-trade 1371990000 4860250000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -10850000 -10900000
(d) Employee benefit expense 119980000 472200000
(e) Finance costs 20800000 86250000
(f) Depreciation, depletion and amortisation expense 65090000 269370000
(f) Other Expenses
1 Other Expenses 102410000 415250000
Total other expenses 102410000 415250000
Total expenses 1864900000 6708600000
3 Total profit before exceptional items and tax 179120000 511720000
4 Exceptional items 0 0
5 Total profit before tax 179120000 511720000
6 Tax expense
7 Current tax 35590000 109220000
8 Deferred tax 3710000 -850000
9 Total tax expenses 39300000 108370000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 139820000 403350000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 139820000 403350000
17 Other comprehensive income net of taxes 2000000 2000000
18 Total Comprehensive Income for the period 141820000 405350000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 239390000 239390000
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve 0
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 1.17 3.37
Diluted earnings (loss) per share from continuing operations 1.17 3.36
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 1.17 3.37
Diluted earnings (loss) per share from continuing and discontinued operations 1.17 3.36
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Notes to the audited standalone financial results: n1.tThe above audited standalone financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited standalone financial results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on May 27, 2025. These financial results have been audited by the Statutory Auditors of the Company and the auditors have expressed an unqualified opinion on the same. n2.tDuring the year ended March 31, 2022, the Company has completed its Initial Public Offering (IPO) of 17,573,342 equity shares of face value of Rs. 2 each for cash at an issue price of Rs. 796 per equity share aggregating to Rs. 13,982.95 million, consisting of Fresh Issue of 7,544,511 equity shares amounting to Rs. 6,000.00 million and an offer for sale of 10,028,831 equity shares amounting to Rs. 7,982.95 million by the Selling Shareholders. Pursuant to the IPO, the equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) with effect from 23 December 2021. n3.tAs per Ind AS 108 'Operating segments', the Company has disclosed the segment information as part of the consolidated financial results. n5.tThe results for the quarter ended March are the balancing amounts between the figures in respect of the full financial year and the published figures up to the third quarter of the respective financial year. n6.tThe earnings per equity share for the quarters are not annualised. n7.tThe above financial results are also available at the Stock Exchange's website i.e. www.bseindia.com, www.nseindia.com and the Company's website www.medplusindia.com. nFor and on behalf of the Board of Directors of nMedPlus Health Services Limited nG. Madhukar Reddy nManaging Director & Chief Executive Officer nDIN: 00098097 nPlace: Hyderabad nDate: May 27, 2025



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1007210000
Capital work-in-progress 12290000
Investment property 0
Goodwill 0
Other intangible assets 17570000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 9282310000
Trade receivables, non-current 0
Loans, non-current 0
Other non-current financial assets 53750000
Total non-current financial assets 9336060000
Deferred tax assets (net) 35970000
Other non-current assets 832680000
Total non-current assets 11241780000
2 Current assets
Inventories 183230000
Current financial asset
Current investments 0
Trade receivables, current 1216210000
Cash and cash equivalents 113000000
Bank balance other than cash and cash equivalents 457220000
Loans, current 0
Other current financial assets 688770000
Total current financial assets 2475200000
Current tax assets (net) 0
Other current assets 94290000
Total current assets 2752720000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 13994500000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 239390000
Other equity 12164080000
Total equity attributable to owners of parent 12403470000
Non controlling interest
Total equity 12403470000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 0
Total non-current financial liabilities 0
Provisions, non-current 16660000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 886410000
Total non-current liabilities 903070000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 28910000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 422740000
Total Trade payable 451650000
Other current financial liabilities 96580000
Total current financial liabilities 548230000
Other current liabilities 116630000
Provisions, current 23100000
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 687960000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1591030000
Total equity and liabilites 13994500000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Remeasurement gain / (loss) on define employee benefit plan 2670000 2670000
Total Amount of items that will not be reclassified to profit and loss 2670000 2670000
2 Income tax relating to items that will not be reclassified to profit or loss 670000 670000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0 0
5 Total Other comprehensive income 2000000 2000000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 511720000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0
Adjustments for decrease (increase) in inventories -43620000
Adjustments for decrease (increase) in trade receivables, current -520330000
Adjustments for decrease (increase) in trade receivables, non-current -6340000
Adjustments for decrease (increase) in other current assets -3920000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current -67440000
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 305640000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities 6540000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 269370000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 17140000
Adjustments for provisions, non-current -9840000
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 86250000
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 11510000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -2550000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) 42410000
Net cash flows from (used in) operations 554130000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 87310000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 466820000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 6180000
Purchase of property, plant and equipment 92370000
Proceeds from sales of investment property 0
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 51580000
Income taxes paid (refund) 0
Other inflows (outflows) of cash -357280000
Net cash flows from (used in) investing activities -391890000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 46320000
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 59200000
Dividends paid 0
Interest paid 86250000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -99130000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -24200000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -24200000
Cash and cash equivalents cash flow statement at beginning of period 137200000
Cash and cash equivalents cash flow statement at end of period 113000000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 B S R and Co Yes 30-Apr-2026


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Sale of goods or services 6274000000 Approved by AC 3167400000 1079500000 1215900000
2 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Purchase of goods or services 2000000 Approved by AC 0 0 0
3 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Sale of goods or services 2500000 Approved by AC 100000 0 0
4 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Management services 38900000 Approved by AC 19400000 0 0
5 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Brand fee 98900000 Approved by AC 51400000 0 0
6 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Availing of services 18300000 Approved by AC 8600000 0 0
7 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Leasing of property 26000000 Approved by AC 10600000 0 0
8 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Letting of property 8800000 Approved by AC 3800000 0 0
9 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Purchase of fixed assets 13000000 Approved by AC 8000000 0 0
10 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Payment made by MedPlus on behalf of Optival 1000000 Approved by AC 0 0 0
11 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Investment 73200000 Approved by AC 18700000 0 0
12 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Jobwork charges 7500000 Approved by AC 5200000 0 0
13 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Coupon collection received 39600000 Approved by AC 5300000 0 0
14 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Any other transaction Coupon collection paid 3200000 Approved by AC 500000 0 0
15 MedPlus Health Services Limited Wynclark Pharmaceuticals Private Limited subsidiary Any other transaction Rendering of services 300000 Approved by AC 100000 300000 0
16 MedPlus Health Services Limited Wynclark Pharmaceuticals Private Limited subsidiary Any other transaction Management services 400000 Approved by AC 100000 0 0
17 MedPlus Health Services Limited Venkata Krishna Enterprises Private Limited subsidiary Any other transaction Share based payment expense 500000 Approved by AC 200000 0 0
18 MedPlus Health Services Limited Kalyani Meditimes Private Limited subsidiary Any other transaction Rendering of services 500000 Approved by AC 0 0 0
19 MedPlus Health Services Limited Kalyani Meditimes Private Limited subsidiary Loan 0 Approved by AC 0 17800000 17800000 Loan 0.18 1 year Unsecured Working capital
20 MedPlus Health Services Limited Kalyani Meditimes Private Limited subsidiary Any other transaction Interest on loan 3200000 Approved by AC 3200000 0 600000
21 MedPlus Health Services Limited Kalyani Meditimes Private Limited subsidiary Any other transaction reimbursement of expenses 200000 Approved by AC 0 0 0
22 MedPlus Health Services Limited Sidson Pharma Distributors Private Limited subsidiary Any other transaction Share based payment expense 100000 Approved by AC 0 0 0
23 MedPlus Health Services Limited MedPlus Insurance Brokering Private Limited subsidiary Any other transaction Rendering of services 500000 Approved by AC 0 0 0
24 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Leasing of property 3000000 Approved by AC 1400000 0 0
25 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Purchase of Moulds 2600000 Approved by AC 2400000 0 800000
26 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Any other transaction Maintenance of Moulds 2000000 Approved by AC 0 0 0
27 MedPlus Health Services Limited Hinshitsu Manufacturing Private Limited Entities Over which share holders, key management personal exercise control or significant influence Purchase of goods or services 500000 Approved by AC 100000 0 0
28 MedPlus Health Services Limited G. Madhukar Reddy Key Managerial personnel Any other transaction Employee Benefits 4000000 Approved by AC 2000000 0 1600000
29 MedPlus Health Services Limited G. Madhukar Reddy Key Managerial personnel Any other transaction Leasing of property 100000 Approved by AC 100000 0 0
30 MedPlus Health Services Limited C Bhaskar Reddy Key Managerial personnel Any other transaction Employee Benefits 13500000 Approved by AC 7100000 0 3800000
31 MedPlus Health Services Limited Sujit Kumar Mahato Key Managerial personnel Any other transaction Employee Benefits 14200000 Approved by AC 8100000 0 0
32 MedPlus Health Services Limited Sujit Kumar Mahato Key Managerial personnel Any other transaction Share based payment expense 7600000 Approved by AC 4500000 0 1000000
33 MedPlus Health Services Limited Manoj Kumar Srivastava Key Managerial personnel Any other transaction Employee Benefits 4900000 Approved by AC 2700000 0 400000
34 MedPlus Health Services Limited Manoj Kumar Srivastava Key Managerial personnel Any other transaction Share based payment expense 1600000 Approved by AC 1200000 0 0
35 MedPlus Health Services Limited Madhavan Ganesan Independent director Remuneration 1400000 Approved by AC 700000 0 0
36 MedPlus Health Services Limited Murali Sivaraman Independent director Remuneration 1300000 Approved by AC 600000 0 0
37 MedPlus Health Services Limited Aparna Surabhi Independent director Remuneration 950000 Approved by AC 650000 0 0
38 MedPlus Health Services Limited Hiroo Mirchandani Independent director Remuneration 400000 Approved by AC 0 0 0
39 MedPlus Health Services Limited Muralidharan Thyagarajan Independent director Remuneration 200000 Approved by AC 200000 0 0
40 MedPlus Health Services Limited MedPlus Employees group gratuity assurance scheme Sister concern Any other transaction Employer contributions for Gratuity fund 7000000 Approved by AC 6600000 0 13600000
41 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Purchase of goods or services 414600000 Approved by AC 75100000 140800000 30300000
42 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Letting of property 300000 Approved by AC 100000 0 0
43 Optival Health Solutions Private Limited Wynclark Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Rendering of services 5400000 Approved by AC 2300000 0 0
44 Optival Health Solutions Private Limited MHS Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Letting of property 200000 Approved by AC 0 0 0
45 Optival Health Solutions Private Limited Sai Sridhar Pharma Private Limited Fellow Subsidiary Purchase of goods or services 5689700000 Approved by AC 1592500000 264500000 217700000
46 Optival Health Solutions Private Limited Sai Sridhar Pharma Private Limited Fellow Subsidiary Any other transaction Rendering of services 1000000 Approved by AC 200000 0 0
47 Optival Health Solutions Private Limited Venkata Krishna Enterprises Private Limited Fellow Subsidiary Purchase of goods or services 6352300000 Approved by AC 2016300000 361600000 327800000
48 Optival Health Solutions Private Limited Venkata Krishna Enterprises Private Limited Fellow Subsidiary Any other transaction Rendering of services 1200000 Approved by AC 400000 0 0
49 Optival Health Solutions Private Limited Deccan Medisales Private Limited Fellow Subsidiary Purchase of goods or services 1980800000 Approved by AC 683500000 73400000 64500000
50 Optival Health Solutions Private Limited Deccan Medisales Private Limited Fellow Subsidiary Any other transaction Rendering of services 2300000 Approved by AC 900000 0 0
51 Optival Health Solutions Private Limited Shri Banashankari Pharma Private Limited Fellow Subsidiary Any other transaction Rendering of services 0 Approved by AC 0 100000 100000
52 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Purchase of goods or services 2093000000 Approved by AC 682600000 150600000 106600000
53 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Any other transaction Leasing of property 1400000 Approved by AC 500000 0 0
54 Optival Health Solutions Private Limited Sidson Pharma Distributors Private Limited Fellow Subsidiary Any other transaction Rendering of services 600000 Approved by AC 100000 0 0
55 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Purchase of goods or services 33800000 Approved by AC 1000000 500000 600000
56 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Letting of property 0 Approved by AC 0 0 0
57 Optival Health Solutions Private Limited Nova Sud Pharmaceuticals Private Limited Fellow Subsidiary Any other transaction Rendering of services 2200000 Approved by AC 0 0 0
58 Optival Health Solutions Private Limited Kalyani Meditimes Private Limited Fellow Subsidiary Any other transaction Letting of property 0 Approved by AC 0 0 0
59 Optival Health Solutions Private Limited Kalyani Meditimes Private Limited Fellow Subsidiary Any other transaction Rendering of services 100000 Approved by AC 0 0 0
60 Optival Health Solutions Private Limited Medplus Insurance Brokers Private Limited Fellow Subsidiary Any other transaction Letting of property 200000 Approved by AC 100000 0 0
61 Optival Health Solutions Private Limited Medplus Insurance Brokers Private Limited Fellow Subsidiary Any other transaction Rendering of services 200000 Approved by AC 0 0 0
62 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Any other transaction Receiving of Job work services 10400000 Approved by AC 6200000 600000 3900000
63 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Any other transaction Rental income 900000 Approved by AC 400000 0 0
64 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Any other transaction Automation Plan Rent Expense 300000 Approved by AC 0 0 0
65 Optival Health Solutions Private Limited Hinshitsu Manufacturing Private Limited entity controlling interest Purchase of goods or services 7000000 Approved by AC 2500000 0 0
66 Optival Health Solutions Private Limited G Madhukar Reddy Key Managerial personnel Any other transaction Leasing of property 4000000 Approved by AC 1900000 0 0
67 Optival Health Solutions Private Limited Madhavan Ganesan Independent director Remuneration 700000 Approved by AC 400000 0 0
68 Optival Health Solutions Private Limited Aparna Surabhi Independent director Remuneration 700000 Approved by AC 400000 0 0
69 Optival Health Solutions Private Limited Optival Employees group gratuity assurance scheme Sister concern Any other transaction Optival Employees group gratuity assurance 80000000 Approved by AC 79500000 0 179800000
70 Optival Health Solutions Private Limited Bhaskar Reddy Hospitals Directors relative is interested Any other transaction Any other transaction Profit Commission 5500000 Approved by AC 2800000 0 0
71 MedPlus Health Services Limited Optival Health Solutions Private Limited subsidiary Sale of fixed assets 4300000 Approved by AC 3000000 0 0
Total value of transaction during the reporting period 8493650000